Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In clinical trials of Tirzepatide, a dual-acting GLP-1 and GIP agonist currently prescribed for Type 2 diabetes, obese patients lost 21 percent body mass in 1.4 years, surpassing the 15 percent reduction seen with Semaglutide
Presented for research literature review only Dziewierz A et al
Research shows that NEAT can decrease by 200 to 500 calories daily after significant weight loss
& Bohr, V
US$ 28.95
US$ 21.17
US$ 21.06
US$ 21.14
US$ 26.19
US$ 22.88
US$ 21.74
US$ 24.32
US$ 29.45
US$ 27.21
US$ 28.02
US$ 21.54
